A novel human multiple myeloma cell line with genetic abnormality of 1q21 gains only and CKS1B overexpression

Abstract

Background Multiple myeloma (MM) remains an incurable hematologic malignancy mainly due to its cytogenetic abnormalities. It is important to establish permanent malignant MM cell lines as effective tools to develop more effective therapies. Results We established and characterized a new multiple myeloma (MM) cell line CZ2 from the pleural effusion of a 70-year-old man. Using nephelometry and flow cytometry, cells with typical plasma cell morphology but not classical plasma cell phenotype were found to be non-immunoglobulin-secretary cells. FISH analysis of cells revealed a unique characteristic that there is only gain of 1q21 region(1q21+), while no other common cytogenetic abnormalities of multiple myeloma such as deletion of 17p(17p-), deletion of 13q(13q-) and translocation of IgH. In addition, the original cell line maintains its single cytogenetic abnormality. Meanwhile, CKS1B, an adverse prognostic gene which is located in 1q21 region was highly expressed in CZ2 using western blotting. Knockdown of CKS1B could reduce cell viability in addition that cleaved PARP and cleaved caspase3 would be decreased. Conclusions Therefore, CZ2 provides a suitable material for cellular and molecular studies of multiple myeloma with only 1q21 abnormality. The cell line characterized by gain of 1q21 and high expression of CKS1B is an important model for studies of myeloma cell growth and drug resistance during therapy.